Clinical Report: EUS-Guided Gastroenterostomy vs Traditional Methods for MGOO

Overview

EUS-Guided Gastroenterostomy (EUS-GE) offers several advantages over traditional methods for managing malignant gastric outlet obstruction (MGOO). These include a significantly lower 6-month reintervention rate, with EUS-GE demonstrating only 4% compared to 29% for uncovered duodenal self-expanding metal stents (SEMS). Additionally, patients undergoing EUS-GE progress to a solid diet more quickly, with a median of 2 days compared to 5 days for surgical gastrojejunostomy (SGJ). The median hospital stay is also shorter for EUS-GE patients, averaging 3 days versus 9 days for SGJ. Furthermore, EUS-GE has shown comparable early adverse outcomes to SGJ while presenting lower total costs, making it a compelling option for patients facing MGOO.

Background

Malignant gastric outlet obstruction is a significant complication in patients with advanced gastrointestinal cancers, leading to severe quality of life impairments. Traditional management options include surgical gastrojejunostomy and enteral stenting, each with distinct benefits and drawbacks. The emergence of EUS-GE presents a potential alternative, warranting comparative evaluation to optimize patient outcomes.

Data Highlights

Key Findings

• EUS-GE significantly reduced 6-month reinterventions compared to uncovered duodenal SEMS (4% vs 29%).

• Patients undergoing EUS-GE advanced to a solid diet faster than those receiving SGJ (median 2 vs 5 days).

• Hospital stays were shorter for EUS-GE patients compared to SGJ (median 3 vs 9 days).

• Early adverse outcomes were comparable between EUS-GE and SGJ.

• EUS-GE demonstrated lower total costs compared to SGJ.

Clinical Implications

EUS-GE may be a preferable option for patients with MGOO due to its lower reintervention rates and quicker recovery times. Clinicians should consider EUS-GE, especially in patients with limited life expectancy or poor functional status, while balancing the need for expertise and appropriate resources.

Conclusion

The findings support the use of EUS-GE as an effective palliative strategy for MGOO, potentially improving patient outcomes compared to traditional methods. Further studies are warranted to solidify its role in clinical practice.

Related Resources & Content

1. DRA-GOO Trial, PubMed, 2025 -- Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction

2. NCCN Guidelines, 2025 -- NCCN Clinical Practice Guidelines in Oncology

3. Endoscopic ultrasonography-guided gastroenterostomy for malignant and benign gastric outlet obstruction: a systematic review and meta-analysis, PMC

4. Comparative Analysis of Endoscopic Stenting and Diverting Stoma as Temporary Solutions Prior to Surgery for Obstructive Colorectal Cancer: A Systematic Review and Meta-Analysis

5. Comparison of Transanal Endoscopic Microsurgery and Radical Resection for Early Rectal Cancer: A Systematic Review and Meta-Analysis

6. Gastric Cancer — Comparison of Open and Minimally Invasive Total Gastrectomy Following Neoadjuvant Chemotherapy: Findings from a European Randomized Study

7. Updates in Surgery — Evaluation of Efficacy, Safety, and Postoperative Quality of Life in Modified Side Overlap Anastomosis Versus Double-Tract Anastomosis Following Laparoscopic Proximal Gastrectomy

8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

9. Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial - PubMed

10. Endoscopic ultrasonography-guided gastroenterostomy for malignant and benign gastric outlet obstruction: a systematic review and meta-analysis - PMC